Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 8 |
| Clinical Trials and Average Enrollment by Country | 7 | 2 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 9 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 10 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 11 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 13 | 1 |
| Clinical Trials by G7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials | 14 | 1 |
| Clinical Trials by Phase in G7 Countries | 15 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 16 | 1 |
| Clinical Trials by E7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials | 17 | 1 |
| Clinical Trials by Phase in E7 Countries | 18 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 19 | 1 |
| Clinical Trials by Phase | 20 | 2 |
| In Progress Trials by Phase | 21 | 1 |
| Clinical Trials by Trial Status | 22 | 1 |
| Clinical Trials by End Point Status | 23 | 1 |
| Subjects Recruited Over a Period of Time | 24 | 1 |
| Clinical Trials by Sponsor Type | 25 | 1 |
| Prominent Sponsors | 26 | 2 |
| Top Companies Participating in Hepatitis C Therapeutics Clinical Trials | 27 | 1 |
| Prominent Drugs | 28 | 1 |
| Latest Clinical Trials News on Hepatitis C | 29 | 4 |
| Aug 11, 2016: New Interim Phase IIa Data on Simeprevir in Combination with Other DAAs Will Be Presented at the Upcoming EASL AASLD Special Conference | 29 | 1 |
| Aug 08, 2016: Results from Merck's Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine | 29 | 1 |
| Jun 21, 2016: Trek Therapeutics Initiates Phase 2a Study of Faldaprevir and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b | 30 | 1 |
| Jun 21, 2016: Ascletis Publishes Interim Data of Phase II Study in Taiwan for its Interferon-free HCV Regimen | 30 | 1 |
| Jun 20, 2016: Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus | 30 | 2 |
| Jun 07, 2016: Regulus Reports Positive Top-line Data | 32 | 1 |
| Clinical Trial Profile Snapshots | 33 | 1711 |
| Appendix | 1744 | 4 |
| Abbreviations | 1744 | 1 |
| Definitions | 1744 | 1 |
| Research Methodology | 1745 | 1 |
| Secondary Research | 1745 | 1 |
| About GlobalData | 1746 | 1 |
| Contact Us | 1746 | 1 |
| Disclaimer | 1746 | 1 |
| Source | 1747 | 1 |